AXGN

AXGN

USD

Axogen Inc. Common Stock

$23.770+0.710 (3.079%)

Reaalajas hind

Healthcare
Meditsiiniseadmed
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$23.060

Kõrge

$23.830

Madal

$22.920

Maht

0.27M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.1B

Tööstusharu

Meditsiiniseadmed

Riik

United States

Kauplemisstatistika

Keskmine maht

1.10M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $9.22Praegune $23.770Kõrge $23.83

Seotud uudised

GlobeNewswire

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,

Vaata rohkem
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $26

HC Wainwright & Co. analyst Yi Chen maintains Axogen with a Buy and raises the price target from $25 to $26.

Vaata rohkem
HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $26
Analyst Upgrades

Raymond James Maintains Outperform on Axogen, Raises Price Target to $27

Raymond James analyst Jayson Bedford maintains Axogen with a Outperform and raises the price target from $20 to $27.

Vaata rohkem
Raymond James Maintains Outperform on Axogen, Raises Price Target to $27
Analyst Upgrades

Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $27

Canaccord Genuity analyst Caitlin Cronin maintains Axogen with a Buy and raises the price target from $24 to $27.

Vaata rohkem
Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $27
Analyst Upgrades

Citizens Maintains Market Outperform on Axogen, Raises Price Target to $34

Citizens analyst David Turkaly maintains Axogen with a Market Outperform and raises the price target from $26 to $34.

Vaata rohkem
Citizens Maintains Market Outperform on Axogen, Raises Price Target to $34
GlobeNewswire

Axogen, Inc. Reports Third Quarter 2025 Financial Results

ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,

GlobeNewswire

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,